GUD Knight Therapeutics Inc
- 5.590
- -0.100-1.76%
Knight Therapeutics Inc News
Knight Therapeutics Inc. (TSE:GUD) Stock Most Popular Amongst Individual Investors Who Own 40%, While Private Companies Hold 25%
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1
Knight Therapeutics Brief: Entering Into Exclusive Supply and Distribution Agreement With Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America
Knight Therapeutics Reports First Quarter 2024 Results
Knight Therapeutics Inc. Announces Voting Results From the Annual General Meeting
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
Knight Therapeutics Inc. Is Maintained at Hold by Stifel Nicolaus
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Knight Therapeutics Inc. Ranks on The Globe and Mail's Fifth-annual Women Lead Here Benchmark of Executive Gender Diversity
Knight Therapeutics Inc. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Knight Therapeutics Inc. Is Maintained at Outperform by RBC Capital
Knight Therapeutics Price Target Raised to $7 at RBC
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q4 2023 Earnings Conference
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
Knight Therapeutics Inc. Is Maintained at Outperform by Raymond James
Stocks in Play: Knight Therapeutics Inc.,
Knight Therapeutics Inc. Celebrates Its First Decade of Success
